1,720,996 research outputs found
sj-zip-1-wso-10.1177_1747493020921664 - Supplemental material for Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature
No full textSupplemental material, sj-zip-1-wso-10.1177_1747493020921664 for Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature by Gaurav Aggarwal Giuseppe Lippi and Brandon Michael Henry in International Journal of Stroke</p
The "olfactory fingerprint": can diagnostics be improved by combining canine and digital noses?
No full textA sniffer (detecting) dog is conventionally defined as an animal trained to use its olfactory perceptions for detecting a vast array of substances, mostly volatile organic compounds (VOCs), including those exceptionally or exclusively generated in humans bearing specific pathologies. Such an extraordinary sniffing performance translates into the capability of detecting compounds close to the femtomolar level, with performance comparable to that of current mass spectrometry-based laboratory applications. Not only can dogs accurately detect "abnormal volatilomes" reflecting something wrong happening to their owners, but they can also perceive visual, vocal and behavioral signals, which altogether would contribute to raise their alertness. Although it seems reasonable to conclude that sniffer dogs could never be considered absolutely "diagnostic" for a given disorder, several lines of evidence attest that they may serve as efficient screening aids for many pathological conditions affecting their human companions. Favorable results have been obtained in trials on cancers, diabetes, seizures, narcolepsy and migraine, whilst interesting evidence is also emerging on the capability of early and accurately identifying patients with infectious diseases. This would lead the way to proposing an "olfactory fingerprint" loop, where evidence that dogs can identify the presence of human pathologies provides implicit proof of the existence of disease-specific volatilomes, which can be studied for developing laboratory techniques. Contextually, the evidence that specific pathologies are associated with abnormal VOC generation may serve as reliable basis for training dogs to detect these compounds, even (or especially) in patients at an asymptomatic phase
Supplemental material for The START nomogram for individualized prediction of the probability of unfavorable outcome after intravenous thrombolysis for stroke
No full textSupplemental material for The START nomogram for individualized prediction of the probability of unfavorable outcome after intravenous thrombolysis for stroke by Manuel Cappellari, Gianni Turcato, Stefano Forlivesi, Fabio Bagante, Gianfranco Cervellin, Giuseppe Lippi, Bruno Bonetti, Paolo Bovi and Danilo Toni in International Journal of Stroke</p
The “olfactory fingerprint”: can diagnostics be improved by combining canine and digital noses?
No full textA sniffer (detecting) dog is conventionally defined as an animal trained to use its
olfactory perceptions for detecting a vast array of substances, mostly volatile organic
compounds (VOCs), including those exceptionally or exclusively generated in humans
bearing specific pathologies. Such an extraordinary sniffing performance translates into
the capability of detecting compounds close to the femtomolar level, with performance
comparable to that of current mass spectrometry-based laboratory applications. Not only
can dogs accurately detect “abnormal volatilomes” reflecting something wrong
happening to their owners, but they can also perceive visual, vocal and behavioral
signals, which altogether would contribute to raise their alertness. Although it seems
reasonable to conclude that sniffer dogs could never be considered absolutely
“diagnostic” for a given disorder, several lines of evidence attest that they may serve as
efficient screening aids for many pathological conditions affecting their human
companions. Favorable results have been obtained in trials on cancers, diabetes,
seizures, narcolepsy and migraine, whilst interesting evidence is also emerging on the
capability of early and accurately identify patients with infectious diseases. This would
lead the way to prosing an “olfactory fingerprint” loop, where evidence that dogs can
identify the presence of human pathologies provides implicit proof of the existence of
disease-specific volatilomes, which can be studied for developing laboratory techniques.
Contextually, the evidence that specific pathologies are associated with abnormal VOCs
generation may serve as reliable basis for training dogs to detect these compounds, even
(or especially) in patients at an asymptomatic phase
sj-pdf-3-pmj-10.1177_02692163221142950 – Supplemental material for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning
No full textSupplemental material, sj-pdf-3-pmj-10.1177_02692163221142950 for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning by Ida J Korfage, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, Guido Miccinesi, Giulia Carreras, Caroline Moeller Arnfeldt, Marijke C Kars, Giuseppe Lippi, Urska Lunder, Ceu Mateus, Kristian Pollock, Luc Deliens, Mogens Groenvold, Agnes van der Heide and Judith AC Rietjens in Palliative Medicine</p
sj-pdf-1-pmj-10.1177_02692163221142950 – Supplemental material for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning
No full textSupplemental material, sj-pdf-1-pmj-10.1177_02692163221142950 for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning by Ida J Korfage, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, Guido Miccinesi, Giulia Carreras, Caroline Moeller Arnfeldt, Marijke C Kars, Giuseppe Lippi, Urska Lunder, Ceu Mateus, Kristian Pollock, Luc Deliens, Mogens Groenvold, Agnes van der Heide and Judith AC Rietjens in Palliative Medicine</p
sj-pdf-6-pmj-10.1177_02692163221142950 – Supplemental material for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning
No full textSupplemental material, sj-pdf-6-pmj-10.1177_02692163221142950 for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning by Ida J Korfage, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, Guido Miccinesi, Giulia Carreras, Caroline Moeller Arnfeldt, Marijke C Kars, Giuseppe Lippi, Urska Lunder, Ceu Mateus, Kristian Pollock, Luc Deliens, Mogens Groenvold, Agnes van der Heide and Judith AC Rietjens in Palliative Medicine</p
sj-pdf-4-pmj-10.1177_02692163221142950 – Supplemental material for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning
No full textSupplemental material, sj-pdf-4-pmj-10.1177_02692163221142950 for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning by Ida J Korfage, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, Guido Miccinesi, Giulia Carreras, Caroline Moeller Arnfeldt, Marijke C Kars, Giuseppe Lippi, Urska Lunder, Ceu Mateus, Kristian Pollock, Luc Deliens, Mogens Groenvold, Agnes van der Heide and Judith AC Rietjens in Palliative Medicine</p
sj-pdf-2-pmj-10.1177_02692163221142950 – Supplemental material for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning
No full textSupplemental material, sj-pdf-2-pmj-10.1177_02692163221142950 for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning by Ida J Korfage, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, Guido Miccinesi, Giulia Carreras, Caroline Moeller Arnfeldt, Marijke C Kars, Giuseppe Lippi, Urska Lunder, Ceu Mateus, Kristian Pollock, Luc Deliens, Mogens Groenvold, Agnes van der Heide and Judith AC Rietjens in Palliative Medicine</p
sj-pdf-5-pmj-10.1177_02692163221142950 – Supplemental material for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning
No full textSupplemental material, sj-pdf-5-pmj-10.1177_02692163221142950 for Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning by Ida J Korfage, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, Guido Miccinesi, Giulia Carreras, Caroline Moeller Arnfeldt, Marijke C Kars, Giuseppe Lippi, Urska Lunder, Ceu Mateus, Kristian Pollock, Luc Deliens, Mogens Groenvold, Agnes van der Heide and Judith AC Rietjens in Palliative Medicine</p
- …
